This content is machine translated Tirzepatide for type 2 diabetes Post-hoc analysis of the SURPASS studies The SURPASS study program investigated the efficacy and safety of the dual GIP/GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. An exploratory analysis of the Phase III SURPASS…
View Post 6 min This content is machine translated Type 2 diabetes: current trends Dual GIP/GLP-1 receptor agonist as an innovative therapeutic option The goals of individualized diabetes treatment today are not limited to achieving glycemic control, but many blood glucose-lowering drugs have clinically relevant additional benefits. Incretin-based therapies are particularly interesting for…
View Post 4 min This content is machine translated Dual GIP/GLP-1 RA in type 2 diabetes Tirzepatide proves multiple benefits In the Phase III SURPASS study program, the dual receptor agonist tirzepatide performed convincingly. The results of several post-hoc analyses are now also available. At the annual meeting of the…
View Post 3 min This content is machine translated GLP-1-RA and dual GLP-1/GIP agonists. Tackling obesity – not only diabetics benefit from the effects While glucagon-like peptide (GLP)-1 receptor agonists have been successfully used in the treatment of diabetes for some time, there are now agents that activate not only the GLP-1 receptor but…